Subscribe to RSS
DOI: 10.1055/s-0041-1733900
What Is the Role of Steroids for Septic Shock in 2021?
![](https://www.thieme-connect.de/media/srccm/202105/lookinside/thumbnails/10-1055-s-0041-1733900_210513-1.jpg)
Abstract
Corticosteroids have been used for decades in the adjunctive treatment of severe infections in intensive care. The most frequent scenario in intensive care is in septic shock, where low doses of glucocorticoids appear to restore vascular responsiveness to norepinephrine. There is a strong body of evidence suggesting that hydrocortisone reduces time on vasopressor, and may modulate the immune response. In this review, we explore the current evidence supporting the use of corticosteroids in septic shock, its benefits, and potential harms. In addition to landmark clinical trials, we will also describe new frontiers for the use of corticosteroids in septic shock which should be explored in future studies.
Publication History
Article published online:
20 September 2021
© 2021. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Young A, Marsh S. Steroid use in critical care. BJA Educ 2018; 18 (05) 129-134
- 2 Annane D, Pastores SM, Arlt W. et al. Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Intensive Care Med 2017; 43 (12) 1781-1792
- 3 Boonen E, Vervenne H, Meersseman P. et al. Reduced cortisol metabolism during critical illness. N Engl J Med 2013; 368 (16) 1477-1488
- 4 Van den Berghe G, Boonen E, Walker BR. Reduced cortisol metabolism during critical illness. N Engl J Med 2013; 369 (05) 481
- 5 Boonen E, Bornstein SR, Van den Berghe G. New insights into the controversy of adrenal function during critical illness. Lancet Diabetes Endocrinol 2015; 3 (10) 805-815
- 6 Patel GP, Balk RA. Systemic steroids in severe sepsis and septic shock. Am J Respir Crit Care Med 2012; 185 (02) 133-139
- 7 Annane D. Corticosteroids for severe sepsis: an evidence-based guide for physicians. Ann Intensive Care 2011; 1 (01) 7
- 8 Marik PE, Pastores SM, Annane D. et al; American College of Critical Care Medicine. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008; 36 (06) 1937-1949
- 9 Annane D, Maxime V, Ibrahim F, Alvarez JC, Abe E, Boudou P. Diagnosis of adrenal insufficiency in severe sepsis and septic shock. Am J Respir Crit Care Med 2006; 174 (12) 1319-1326
- 10 Annane D, Sébille V, Troché G, Raphaël JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000; 283 (08) 1038-1045
- 11 Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332 (20) 1351-1362
- 12 Annane D. Neuroimmunomodulation in sepsis. Inflamm Res 2011; 60: S27-S28
- 13 Fernandes ABS, Zin WA, Rocco PRM. Corticosteroids in acute respiratory distress syndrome. Braz J Med Biol Res 2005; 38 (02) 147-159
- 14 van Leeuwen HJ, van der Bruggen T, van Asbeck BS, Boereboom FTJ. Effect of corticosteroids on nuclear factor-kappaB activation and hemodynamics in late septic shock. Crit Care Med 2001; 29 (05) 1074-1077
- 15 Klaitman V, Almog Y. Corticosteroids in sepsis: a new concept for an old drug. Isr Med Assoc J 2003; 5 (01) 51-55
- 16 Keh D, Boehnke T, Weber-Cartens S. et al. Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003; 167 (04) 512-520
- 17 Lambden S, Creagh-Brown BC, Hunt J, Summers C, Forni LG. Definitions and pathophysiology of vasoplegic shock. Crit Care 2018; 22 (01) 174
- 18 Hadoke PWF, Macdonald L, Logie JJ, Small GR, Dover AR, Walker BR. Intra-vascular glucocorticoid metabolism as a modulator of vascular structure and function. Cell Mol Life Sci 2006; 63 (05) 565-578
- 19 Levy B, Fritz C, Tahon E, Jacquot A, Auchet T, Kimmoun A. Vasoplegia treatments: the past, the present, and the future. Crit Care 2018; 22 (01) 52
- 20 Radomski MW, Palmer RMJ, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A 1990; 87 (24) 10043-10047
- 21 Löwenberg M, Stahn C, Hommes DW, Buttgereit F. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids 2008; 73 (9-10): 1025-1029
- 22 Perla D, Marmorston J. Suprarenal cortical hormone and salt in the treatment of pneumonia and other severe infections. Endocrinology 1940; 27: 367-374
- 23 Bone RC, Fisher Jr CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317 (11) 653-658
- 24 Sprung CL, Caralis PV, Marcial EH. et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984; 311 (18) 1137-1143
- 25 Cronin L, Cook DJ, Carlet J. et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23 (08) 1430-1439
- 26 Lefering R, Neugebauer EAM. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995; 23 (07) 1294-1303
- 27 Annane D, Sébille V, Charpentier C. et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288 (07) 862-871
- 28 Sprung CL, Annane D, Keh D. et al; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358 (02) 111-124
- 29 Dellinger RP, Levy MM, Rhodes A. et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41 (02) 580-637
- 30 Annane D, Renault A, Brun-Buisson C. et al; CRICS-TRIGGERSEP Network. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 2018; 378 (09) 809-818
- 31 Venkatesh B, Finfer S, Cohen J. et al; ADRENAL Trial Investigators and the Australian–New Zealand Intensive Care Society Clinical Trials Group. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 2018; 378 (09) 797-808
- 32 Wang C, Sun J, Zheng J. et al. Low-dose hydrocortisone therapy attenuates septic shock in adult patients but does not reduce 28-day mortality: a meta-analysis of randomized controlled trials. Anesth Analg 2014; 118 (02) 346-357
- 33 Minneci PC, Deans KJ, Eichacker PQ, Natanson C. The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clin Microbiol Infect 2009; 15 (04) 308-318
- 34 Sligl WI, Milner Jr DA, Sundar S, Mphatswe W, Majumdar SR. Safety and efficacy of corticosteroids for the treatment of septic shock: a systematic review and meta-analysis. Clin Infect Dis 2009; 49 (01) 93-101
- 35 Annane D, Bellissant E, Bollaert P-E. et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009; 301 (22) 2362-2375
- 36 Lian XJ, Huang DZ, Cao YS. et al. Reevaluating the role of corticosteroids in septic shock: an updated meta-analysis of randomized controlled trials. BioMed Res Int 2019; 2019: 3175047
- 37 Rygård SL, Butler E, Granholm A. et al. Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 2018; 44 (07) 1003-1016
- 38 Batzofin BM, Sprung CL, Weiss YG. The use of steroids in the treatment of severe sepsis and septic shock. Best Pract Res Clin Endocrinol Metab 2011; 25 (05) 735-743
- 39 Santhakumaran S, Gordon A, Prevost AT, O'Kane C, McAuley DF, Shankar-Hari M. Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials. Crit Care 2019; 23 (01) 156
- 40 Antcliffe DB, Burnham KL, Al-Beidh F. et al. Transcriptomic signatures in sepsis and a differential response to steroids from the VaNISH randomized trial. Am J Respir Crit Care Med 2019; 199 (08) 980-986
- 41 Venkatesh B, Cohen J. Why the Adjunctive Corticosteroid Treatment in Critically Ill Patients With Septic Shock (ADRENAL) trial did not show a difference in mortality. Crit Care Med 2019; 47 (12) 1785-1788
- 42 Fang F, Zhang Y, Tang J. et al. Association of corticosteroid treatment with outcomes in adult patients with sepsis: a systematic review and meta-analysis. JAMA Intern Med 2019; 179 (02) 213-223
- 43 Thille AW, Cortés-Puch I, Esteban A. Weaning from the ventilator and extubation in ICU. Curr Opin Crit Care 2013; 19 (01) 57-64
- 44 Keh D, Trips E, Marx G. et al; SepNet–Critical Care Trials Group. Effect of hydrocortisone on development of shock among patients with severe sepsis the HYPRESS randomized clinical trial. JAMA 2016; 316 (17) 1775-1785
- 45 Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26 (04) 645-650
- 46 Nethathe GD, Cohen J, Lipman J, Anderson R, Feldman C. Mineralocorticoid dysfunction during critical illness: a review of the evidence. Anesthesiology 2020; 133 (02) 439-457
- 47 Hamitouche N, Comets E, Ribot M, Alvarez JC, Bellissant E, Laviolle B. Population pharmacokinetic-pharmacodynamic model of oral fludrocortisone and intravenous hydrocortisone in healthy volunteers. AAPS J 2017; 19 (03) 727-735
- 48 Polito A, Hamitouche N, Ribot M. et al. Pharmacokinetics of oral fludrocortisone in septic shock. Br J Clin Pharmacol 2016; 82 (06) 1509-1516
- 49 Annane D, Cariou A, Maxime V. et al; COIITSS Study Investigators. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 2010; 303 (04) 341-348
- 50 Keh D, Weber-Carstens S, Ahlers O. Adjunctive therapies in severe sepsis and septic shock: current place of steroids. Curr Infect Dis Rep 2008; 10 (05) 354-361
- 51 Hammond NE, Finfer SR, Li Q. et al; ADRENAL Trial Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Health-related quality of life in survivors of septic shock: 6-month follow-up from the ADRENAL trial. Intensive Care Med 2020; 46 (09) 1696-1706
- 52 Thompson K, Venkatesh B, Hammond N, Taylor C, Finfer S. The ADRENAL Investigators, Sex-Disaggregated Analysis Steering Committee. Sex differences in response to adjunctive corticosteroid treatment for patients with septic shock. Intensive Care Med 2021; 47 (02) 246-248
- 53 Abdallah MS. The best use of systemic corticosteroids in the intensive care units. Review J Steroids Horm Sci 2015; 06: 1-6
- 54 Laviolle B, Annane D, Fougerou C, Bellissant E. Gluco- and mineralocorticoid biological effects of a 7-day treatment with low doses of hydrocortisone and fludrocortisone in septic shock. Intensive Care Med 2012; 38 (08) 1306-1314
- 55 Kramer CL. Intensive care unit-acquired weakness. Neurol Clin 2017; 35 (04) 723-736
- 56 Yang T, Li Z, Jiang L, Xi X. Corticosteroid use and intensive care unit-acquired weakness: a systematic review and meta-analysis. Crit Care 2018; 22 (01) 187
- 57 Finfer S, Wernerman J, Preiser JC. et al. Clinical review: consensus recommendations on measurement of blood glucose and reporting glycemic control in critically ill adults. Crit Care 2013; 17 (03) 229
- 58 Lindner G, Funk GC. Hypernatremia in critically ill patients. J Crit Care 2013; 28 (02) 216.e11-216.e20
- 59 Krinsley JS, Preiser JC. Is it time to abandon glucose control in critically ill adult patients?. Curr Opin Crit Care 2019; 25 (04) 299-306
- 60 Honiden S, Inzucchi SE. Metabolic management during critical illness: glycemic control in the ICU. Semin Respir Crit Care Med 2015; 36 (06) 859-869
- 61 Patel AK, Hollenberg SM. Cardiovascular failure and cardiogenic shock. Semin Respir Crit Care Med 2011; 32 (05) 598-606
- 62 Russell JA, Walley KR, Gordon AC. et al; Dieter Ayers for the Vasopressin and Septic Shock Trial Investigators. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009; 37 (03) 811-818
- 63 Annane D. Vasopressin plus corticosteroids: the shock duo!. Crit Care Med 2009; 37 (03) 1126-1127
- 64 Gordon AC, Mason AJ, Thirunavukkarasu N. et al; VANISH Investigators. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 2016; 316 (05) 509-518
- 65 Ranieri VM, Thompson BT, Barie PS. et al; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366 (22) 2055-2064
- 66 Póvoa P, Salluh JIF, Martinez ML. et al. Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial. Crit Care 2015; 19 (01) 193
- 67 Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study. Chest 2017; 151 (06) 1229-1238
- 68 Rubin R. Wide interest in a vitamin C drug cocktail for sepsis despite lagging evidence. JAMA 2019; 322 (04) 291-293
- 69 Moskowitz A, Andersen LW, Huang DT. et al. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. Crit Care 2018; 22: 1261-1270
- 70 Fujii T, Luethi N, Young PJ. et al; VITAMINS Trial Investigators. Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: the VITAMINS randomized clinical trial. JAMA 2020; 323 (05) 423-431